Escaping big pharma’s pricing with patent-free drugs But clearly there’s room for more nonprofit drug companies. “D.N.D.I.’s success is ample proof that the model of nonprofit, open-source research and development is a viable alternative to exclusive reliance on patent and data monopolies,” said Brook Baker, a professor at Northeastern University School of Law who studies pharmaceutical development issues. Recent reports on the […]